Icon
+91 94997 68112
Login Register

Tykerb - (EQ 250MG BASE; Tablet)

Lapatinib Ditosylate Novartis
EQ 250MG BASE; Tablet
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
 None
Less Than 5
Less Than 5
TYKERB is a kinase inhibitor indicated in combination with: • capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab. • letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated.
Yes
***** ** ******** **** ***** ***** * **** ** **** ****** *** *** *** ********* ** ***. ** ****** **** *** ******** ***** **** *** **** ****** ******* ******** ** *** **, **** *** * **** ** **** ******* ******* - *** **, ****; ******* - *** **, ****. **** ******** **** *** ** **** ** ***** **** *** **, ****.
Tykerb Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
***** (*****) **** *** *** ********* *** ********* *** ********* *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** (*****) *** \ ** *** ********* *** ********* ********* ******** ******** ** ** ***, ****
  1. **** **. **** : ***** & ***** ******** ***** ***** ***** **** ** ****** **** ******. ***** *** *** **** * **** ******* ***** & *****.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.